The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial

BACKGROUND: Levetiracetam and zonisamide are licensed as monotherapy for patients with focal epilepsy, but there is uncertainty as to whether they should be recommended as first-line treatments because of insufficient evidence of clinical effectiveness and cost-effectiveness. We aimed to assess the...

Descripción completa

Detalles Bibliográficos
Autores principales: Marson, Anthony, Burnside, Girvan, Appleton, Richard, Smith, Dave, Leach, John Paul, Sills, Graeme, Tudur-Smith, Catrin, Plumpton, Catrin, Hughes, Dyfrig A, Williamson, Paula, Baker, Gus A, Balabanova, Silviya, Taylor, Claire, Brown, Richard, Hindley, Dan, Howell, Stephen, Maguire, Melissa, Mohanraj, Rajiv, Smith, Philip E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8047799/
https://www.ncbi.nlm.nih.gov/pubmed/33838757
http://dx.doi.org/10.1016/S0140-6736(21)00247-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8047799/
https://www.ncbi.nlm.nih.gov/pubmed/33838757
http://dx.doi.org/10.1016/S0140-6736(21)00247-6

Ejemplares similares